Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

136.54USD
7:18pm GMT
Change (% chg)

$-0.37 (-0.27%)
Prev Close
$136.91
Open
$136.91
Day's High
$137.00
Day's Low
$135.78
Volume
526,216
Avg. Vol
2,748,019
52-wk High
$148.97
52-wk Low
$118.62

Select another date:
Photo

Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 million

Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits alleging that their blockbuster blood thinner Xarelto caused unstoppable and in some cases fatal bleeding for a total of $775 million (588 million pounds), court documents on Monday showed.

Bayer, J&J settle U.S. Xarelto litigation for $775 million

Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million, court documents on Monday showed.

UPDATE 2-Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 mln

March 25 Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits alleging that their blockbuster blood thinner Xarelto caused unstoppable and in some cases fatal bleeding for a total of $775 million, court documents on Monday showed.

Bayer, J&J settle U.S. Xarelto litigation for $775 mln

March 25 Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million, court documents on Monday showed.

J&J to record $700 million charge related to abandoned drug program

Johnson & Johnson on Thursday said https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm it will record a nearly $700 million (£536.4 million) impairment charge in the first quarter of 2019 related to the abandoned development of its experimental antiviral drug, AL-8176.

J&J to record $700 million charge related to abandoned drug program

Johnson & Johnson on Thursday said it will record a nearly $700 million impairment charge in the first quarter of 2019 related to the abandoned development of its experimental antiviral drug, AL-8176.

J&J to record $700 mln charge related to abandoned drug program

March 21 Johnson & Johnson on Thursday said https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm it will record a nearly $700 million impairment charge in the first quarter of 2019 related to the abandoned development of its experimental antiviral drug, AL-8176.

J&J and Sientra get FDA warning letters over breast implants

The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants.

UPDATE 3-J&J and Sientra get FDA warning letters over breast implants

March 19 The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants.

California jury awards $29 million to woman with cancer who used J&J talc

A California jury on Wednesday awarded $29 million to a woman who said that asbestos in Johnson & Johnson's talcum-powder-based products caused her cancer.

Select another date: